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Imaging of infectious diseases using
[18F]fluorodeoxyglucose PET
C. P. BLEEKER-ROVERS 1, 2, F. J. VOS 1, 2, F. H. M. CORSTENS 2, 3, W. J. G.OYEN 2, 3
The role of fluorodeoxyglucose positron emission tomo-
graphy (FDG PET) in the diagnostic localization of infec-
tious diseases has expanded rapidly in recent years. In
general, sensitivity of FDG PET in depicting infections
compares favorably to other diagnostic modalities. It is
shown to be useful in patients with suspected osteomyelitis,
especially in chronic low-grade infections and in verte-
bral osteomyelitis. Although the sensitivity of FDG PET in
prosthetic joint infections is very high, reported speci-
ficity varies considerably. In experienced centers, FDG
uptake localized along the interface between bone and
prosthesis can be used to diagnose infection with accept-
able specificity. Combined leukocyte scintigraphy and
bone scanning, however, remains the standard scinti-
graphic method for diagnosis of infected joint prosthe-
ses. FDG PET has shown promising results in vascular
graft infections, in the evaluation of metastatic infectious
foci in patients with blood stream infections and in neu-
tropenic patients, but further studies are needed before
definitive conclusions can be drawn. In fever of unknown
origin (FUO), FDG PET appears to be of great advantage as
malignancy, inflammation and infection can be detected.
Image fusion combining PET and computed tomography
facilitates anatomical localization of increased FDG uptake
and better guiding for further diagnostic tests to achieve
a final diagnosis. In conclusion, the body of evidence on
the utility of FDG PET in infectious diseases and FUO is
growing and FDG PET may become one of the preferred
diagnostic procedures for many of these diseases, espe-
cially when a definite diagnosis cannot easily be achieved.
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computed - Infection - Fever of unknown origin.
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Fluorine-18(18F)-fluorodeoxyglucose positron emis-sion tomography (FDG PET) has been an estab-
lished diagnostic tool in oncology since many years
and the indications for FDG PET are expanding rapid-
ly. FDG accumulates in all tissues with a high rate of
glycolysis, which not exclusively occurs in neoplastic
cells. FDG uptake is also present in all activated leuko-
cytes (granulocytes, monocytes as well as lympho-
cytes) enabling imaging of acute and chronic inflam-
matory processes. The mechanism of FDG uptake in
activated leukocytes is related to the fact that these
cells use glucose as an energy source only after acti-
vation during the metabolic burst. FDG, like glucose,
passes the cell membrane. Phosphorylated FDG is
not further metabolized and remains trapped inside the
cell, in contrast to phosphorylated glucose that enters
the glycolytic pathway. Increased uptake and reten-
tion of FDG has been shown in lesions with a high
concentration of inflammatory cells, such as granu-
locytes and activated macrophages. In an experi-
mental rat model of turpentine-induced inflamma-
tion, FDG uptake was elevated even more in chron-
ic inflammation than in an acute inflammatory
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process.1 In another rat model of Escherichia coli
infection, the uptake of FDG in the infectious process
was higher than that of [67Ga]citrate, radiolabeled
thymidine, methionine and human serum albumin.2
FDG PET has several advantages as compared to
conventional scintigraphic techniques. Physiological
uptake of FDG is low in most organs (except for the
brain, heart, kidneys, and bladder) and provides rel-
atively high target to background ratios. Low normal
organ uptake is best assured by injecting FDG during
a normoglycemic, hypo-insulinemic state created by
a 6 h fasting period.3, 4 FDG PET provides high-reso-
lution, three-dimensional images of the whole body.
Early imaging after 1 h is possible, resulting in early
reporting. Furthermore, the dosimetry of FDG com-
pares favorably to conventional radiopharmaceuti-
cals. Although increased glucose metabolism may
correlate with structural anatomical damage as depict-
ed by conventional radiological techniques, FDG PET
depicts functional changes in tissue, which may often
precede anatomical changes. It may be difficult to
detect active disease in scar tissue using convention-
al radiological techniques while one of the strong-
holds of FDG PET is the delineation of disease activ-
ity. Co-registration of PET and computed tomogra-
phy (CT) in combined PET-CT scanners, improves
the interpretation of the PET findings by exact local-
ization of lesions.5
Search of the literature
For the period 1980-January 2007, the National
Library of Medicine (PubMed) was searched using
the basic search terms for FDG PET studies as pro-
posed by Mijnhout et al.6 Subsequently, the above
string was combined with infection, osteomyelitis,
fever of unknown origin (FUO), or pyrexia of
unknown origin. Additional search terms ‘bacter-
aemia’, ‘bacterial infection’ were subsequently used,
but did not reveal studies not already retrieved. A
search in the Cochrane database only resulted in
reviews focussing on the use of PET in various malig-
nant diseases. No studies were found in the current
controlled trials database.
After exclusion of publications written in a lan-
guage other than English, a total number of 237 pub-
lications were retrieved. First, all publications address-
ing topics other than infection and FUO were exclud-
ed. The remaining publications (n=174) were divided
into reviews, editorials, and case reports or case series
including less than 3 patients (n=106). Clinical stud-
ies primarily aimed at diagnosing infection or FUO
(n=68) were arranged according to organ system or
anatomic site(s) of localization7-74 (Table I).
Abdominal infection
In 1989, Tahara et al. were the first to report
increased FDG uptake in 2 patients with abdominal
abscesses.7 Numerous reports regarding FDG uptake
in infectious and inflammatory diseases followed. In
patients with polycystic kidney disease, FDG PET
proved to be very helpful in 7 episodes of suspected
renal or hepatic cyst infection by correctly pointing to
the infected cysts.8 A follow-up PET scan showed
complete normalization after 6 weeks of treatment in
one patient and ruled out re-infection in a subsequent
episode of fever in another patient. In 12 inoperable
patients with alveolar echinococcosis of the liver,
Reuter et al. evaluated the glucose metabolism of
lesions by use of FDG PET.9 Necrotic parasitic lesions
and areas of enhanced metabolic activity could be
clearly discriminated. Most notably, 3 of 8 patients
with metabolically active lesions, who were re-exam-
ined after chemotherapeutic treatment clearly showed
improvement. In another study, PET showed increased
FDG uptake in 21/26 patients with newly diagnosed
alveolar echinococcosis and in only 1 of 12 patients
with newly diagnosed cystic echinococcosis.10 In 5
of 10 patients with non-resectable disease and
increased baseline FDG uptake, the intensity of uptake
decreased (or disappeared) during benzimidazole
TABLE I.—References arranged according to organ system or loca-
lization.
Type of infection References
Abdominal infection 7-10
Chest infection 11-13
Osteomyelitis 14-31
Prosthetic joint infection 18, 21, 32-45
Postoperative infections 21, 22, 46
Vascular infections 18, 47-50
Metastatic infectious foci 51
The immunocompromised host 52-63
Miscellaneous infections 17, 33, 64-67
Fever of unknown origin 65, 68-73
Differentiation between infection and malignancy 31, 74
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therapy. It is concluded that FDG PET is a sensitive
and specific adjunct in the diagnosis of suspected
alveolar echinococcosis and can help in differentiat-
ing alveolar from cystic echinococcosis in the liver.
FDG PET also appears to be valuable in assessing the
efficacy of chemotherapy by showing the disappear-
ance of metabolic activity.
Chest infection
There have been numerous reports about FDG
uptake in pulmonary infection and inflammation,
most arising from false positive results in studies on
the use of FDG PET in oncology. Bakheet et al.
reviewed 650 FDG PET scans performed in patients
suspected of lung cancer. In 10 patients pulmonary
FDG uptake mimicked pulmonary metastases, but
proved to be caused by benign disease.11 In another
study in a region with a high incidence of pulmonary
histoplasmosis, sensitivity of FDG PET, as assessed
in 84 patients with solitary pulmonary nodules, was
93% for diagnosing non-small cell lung cancer, but
specificity was only 40%.12 In 97 patients with untreat-
ed lung cancer, 14 patients with untreated pulmonary
tuberculosis, and 5 patients with untreated atypical
mycobacterial infection, standardized uptake values
(SUV) of FDG and of [11C]choline were compared
using PET.13 SUV of FDG was highest in patients with
lung cancer, lower in patients with tuberculosis and
lowest in patients with atypical mycobacterial infec-
tion, but there was considerable overlap in SUV of
both FDG and [11C]choline. This underlines the con-
clusion that FDG PET is not able to make a definite dif-
ferentiation between malignancy and infection on an
individual patient basis.
Osteomyelitis
FDG PET has been used successfully in diagnosing
acute osteomyelitis,14 but it has no added value to
physical examination, laboratory results, three-phase
bone scanning and MRI in the absence of complicat-
ing factors. The diagnosis of chronic osteomyelitis is
more complex. In patients with chronic osteomyelitis,
excellent accuracy was found for FDG PET compa-
rable to scintigraphy with antigranulocyte antibodies
and 111In-labeled leukocytes.14-19 In the central skele-
ton, accuracy of FDG PET was even higher than for
111In-labeled leukocytes and antigranulocyte antibody
scintigraphy.15, 16 In a prospective study including 31
patients suspected of osteomyelitis (peripheral skele-
ton: n=21 and central skeleton: n=10), overall accuracy
of FDG PET was 97% with a high degree of interob-
server concordance.20 In another study, sensitivity,
specificity, and accuracy of FDG PET were 100%,
88%, and 93% in 60 patients with a suspected chron-
ic musculoskeletal infection involving the central
skeleton (n=33) or the peripheral skeleton (n=27).21
Hartmann et al. studied the use of FDG PET-CT in 33
trauma patients suspected of chronic osteomyelitis
(23 peripheral skeleton, 10 central skeleton).22
Sensitivity, specificity and accuracy for the whole
group were 94%, 87% and 91%.
In 42 patients suspected of chronic osteomyelitis of
the mandible, sensitivity of FDG PET (64%) was low-
er than sensitivity of bone scintigraphy (84%), but
specificity of FDG PET proved to be higher (78% vs
33%).23 During follow-up, specificity of FDG PET was
still 63% while specificity of bone scintigraphy
decreased to <10%. In 14 patients with diabetic foot
infections, suspected of underlying osteomyelitis, PET-
CT correctly localized the infectious foci in 4 patients
to bone.24 PET-CT correctly excluded osteomyelitis
in 5 patients, with the abnormal FDG uptake limited
to infected soft tissues only. One site of mildly
increased focal FDG uptake was localized by PET-
CT to diabetic osteoarthropathy changes demonstrat-
ed on CT. Four patients showed no abnormally
increased FDG uptake and no further evidence of an
infectious process on clinical and imaging follow-up.
It is well known that acute fractures can result in
increased FDG accumulation and, therefore, cause
difficulties when patients are evaluated for other indi-
cations by FDG PET. Zhuang et al. retrospectively
assessed the pattern and time course of abnormal
FDG uptake following traumatic or surgical fracture in
1 517 consecutive patients, who underwent whole-
body FDG PET imaging.25 Thirty-seven patients with
a known date of traumatic or surgical fracture were
identified. In 14 patients with fractures, less than 3
months old, only 6 had abnormally increased FDG
uptake. In 23 patients with fractures, more than 3
months old, only one patient showed increased FDG
uptake, which was shown to be a result of compli-
cating osteomyelitis. It is concluded that FDG uptake
is expected to be normal within 3 months following
traumatic or surgical fractures.
MI
NE
RV
A M
ED
IC
A
CO
PY
RI
GH
T®
BLEEKER-ROVERS IMAGING OF INFECTIOUS DISEASES USING [18F]FLUORODEOXYGLUCOSE PET
20 THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING March 2008
The usefulness of antigranulocyte antibody or radi-
olabeled leukocyte scintigraphy is low in the central
skeleton due to physiological uptake in normal bone
marrow. In several studies, FDG PET enabled correct
visualization of vertebral osteomyelitis.26-28 FDG PET
proved to be superior to MRI, [67Ga]citrate scintigraphy
and 3 phase bone scan in these patients, especially in
patients with low-grade vertebral osteomyelitis (as
compared with magnetic resonance imaging (MRI),
adjacent soft tissue infections (as compared with
[67Ga]citrate) and advanced bone degeneration (as
compared with [99mTc]MDP).26, 27 FDG PET was also
able to differentiate between mild infection and degen-
erative changes.27 In another study including 56
patients suspected of having spinal infection after
previous surgery of the spine, sensitivity, specificity
and accuracy of FDG PET were 100%, 81%, and 86%,
respectively.29 In the group without metallic implants
(n=27), false positives (n=2) only occurred in the first
6 months after surgery. In the group with metallic
implants (n=30), false positives (n=6) were not con-
fined to recently operated patients. It is concluded
that FDG PET holds promise to become the standard
imaging technique in this difficult patient population,
especially after previous surgery, as it is straightforward
and provides a rapid result. PET images are not dis-
turbed by the presence of metallic implants, which is
a major advantage when compared to CT and MRI. In
addition, FDG PET is a very sensitive tool even for
chronic and low-grade infections.
De Winter et al. evaluated the feasibility of dual-
head γ-camera coincidence (DHC) imaging in 24
patients, referred for the confirmation or exclusion
of orthopedic infection.30 Despite lower image qual-
ity for FDG DHC imaging, results in this limited series
were comparable with the results of FDG dedicated
PET. In conclusion, FDG PET is very useful in cases
of suspected osteomyelitis of the central skeleton or
chronic low-grade infections of the peripheral skele-
ton.
Prosthetic joint infection
The most frequent complications of joint arthro-
plasty are infection or aseptic loosening of the pros-
thesis. Preoperative differentiation is essential, since
optimal surgical treatment depends on the correct
diagnosis. Diagnosing prosthetic joint infection is very
difficult, because radiographic methods and three-
phase bone scanning cannot differentiate adequate-
ly between septic and aseptic loosening. FDG PET is
very sensitive in detecting infected joint prostheses, but
specificity varies from approximately 50% to 95% in lit-
erature.21, 32-37, 46, 75 When compared to three-phase
bone scanning, both sensitivity and specificity of FDG
PET proved to be higher in patients with suspected
infection of total hip prostheses.36, 38 In a prospective
study in 35 patients with painful hip prostheses by
Stumpe et al., however, FDG PET was more specific,
but less sensitive than conventional radiography for the
diagnosis of infection.39 In this study, sensitivity and
specificity of FDG PET was comparable to three-phase
bone scanning.
In a retrospective study including 97 patients sus-
pected of infection of orthopedic hardware, accura-
cy of FDG PET was 96% for hip prosthesis, 81% for
knee prosthesis and 100% in 15 patients with other
orthopedic devices.18 Among the 23 patients, who
had recent orthopedic procedures, FDG PET imaging
was accurate in 87% of cases. In a study by Zhuang
et al., accuracy of FDG PET was also higher in patients
suspected of infected hip prostheses than in patients
suspected of infected knee prostheses (90% vs 78%).37
In a prospective study comparing FDG PET to 99mTc-
labeled leukocytes in combination with bone scintig-
raphy in patients suspected of infected hip prosthe-
ses and in controls with asymptomatic hip prostheses,
the combined analysis of bone scintigraphy and
leukocyte scintigraphy resulted in a comparable sen-
sitivity, but a lower specificity for FDG PET.40 Pill et
al. compared the accuracy of FDG PET with 99mTc-col-
loid-111In-labeled leukocytes in 89 patients with 92
painful hip prostheses.41 Sensitivity of FDG PET was
considerably higher (95% vs 50%) while specificity
was comparable to scintigraphy with 99mTc-colloid-
111In-labeled leukocytes (93% vs 95%). In a study by
Van Acker et al. comparing combined three-phase
bone scanning and 99mTc-labeled leukocyte scintig-
raphy with FDG PET in 21 patients with painful knee
arthroplasties, sensitivity of both techniques was
100% while specificity of FDG PET proved to be low-
er (80% vs 93%).42
Stumpe et al. evaluated FDG uptake in 28 patients
with painful knee prostheses.43 Diffuse synovial and
focal extra-synovial FDG uptake was found in patients
with malrotation of the femoral component and was
not related to pain location. In this study, the infor-
mation provided by FDG PET did not contribute to the
diagnosis and management of individual patients with
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persistent pain after total knee replacement. Zhuang
et al. have shown in a small prospective study of 9
patients with uncomplicated hip prostheses that
increased FDG uptake around the femoral head or
neck portion of the prosthesis with extension to the
soft tissues surrounding the femur persisted up until
1 year after surgery.44 In a larger retrospective study,
increased FDG uptake around the femoral head or
neck portion was found in 81% of 21 uncomplicated
hip prostheses with an average time interval between
surgery and FDG PET of 71 months.44 In a study of 41
total hip arthroplasties from 32 patients by Chacko
et al., increased FDG uptake was found along the
interface between bone and the intensity of the FDG
uptake varied from mild to moderate in patients with
infection.45 In contrast, images from uninfected, loose
hip prostheses revealed very intense uptake around
the head or neck of the prosthesis with SUV as high
as 7. It is concluded that the intensity of increased
FDG uptake is less important than the location of
increased FDG uptake when FDG PET is used to diag-
nose periprosthetic infection in patients with hip
arthroplasty.
It is concluded that FDG PET has a high sensitivi-
ty in diagnosing infected joint prostheses. Specificity,
however, is lower than specificity of combined leuko-
cyte scintigraphy and bone scanning. This limited
specificity probably results from persisting FDG uptake
around the prosthesis for many years after arthro-
plasty, even in uncomplicated cases.44, 75 Location of
FDG uptake is probably important since FDG uptake
along the interface between bone and prosthesis
appears to be a more specific pattern of imaging for
infection.
Postoperative infections
In the study by Hartmann et al., showing an accu-
racy of FDG PET-CT of 91% in 33 trauma patients sus-
pected of chronic osteomyelitis, 18 patients with metal-
lic implants were included.22 PET results were not
affected by attenuation correction artefacts due to the
metallic implants (n=15) used in trauma surgery, but
no information was provided about the time between
insertion of these implants and FDG PET. In patients
with prosthetic devices (n=3), the non attenuation-
corrected scans showed no FDG uptake at sites where
the attenuation-corrected images were FDG positive.
The authors speculate that this can be explained by the
lower photon absorption of the slender metallic instru-
mentation used in trauma surgery, in contrast to the
joint arthroplasties with a high photon absorption used
in orthopedic surgery. De Winter et al. studied the
value of FDG PET in 35 patients with surgery in the
previous 2 years who were suspected of harboring a
chronic musculoskeletal infection.21 Accuracy was
94%, which was comparable to patients without recent
surgery in the same study. In a prospective study by
Schiesser et al., 29 partial-body FDG PET scans in 22
patients suspected of having metallic implant-associ-
ated infections were obtained.46 The interval between
the last surgical intervention and the time of PET scan-
ning ranged between 6 weeks and 14 months.
Sensitivity, specificity, and accuracy were 100%, 93%,
and 97%, respectively. FDG PET appears to be a sen-
sitive and specific method for the detection of infectious
foci due to metallic implants in patients with trauma,
even in patients within 1 year after surgery.
FDG uptake in physiological wound healing is
expected to diminish over time. In a German study
exploring the value of FDG PET in 18 patients with
suspected postoperative infections, sensitivity and
specificity of infection imaging in areas outside the
region of surgical trauma were 86% and 100%.
Sensitivity of infection imaging in the area of the sur-
gical wound was 100%, while specificity was only
56%.76 The interval between surgery and FDG PET
was significantly shorter in patients with false positive
results. Further studies on the degree, pattern and
duration of physiological FDG uptake after surgery are
warranted.
Vascular infections
Aortic prosthetic graft infection is associated with
high morbidity and mortality in the absence of imme-
diate, definitive antibiotic therapy and surgical inter-
vention. CT has been used as a complementary imag-
ing approach for the assessment of graft infection.
However, hematomas and seromas in the vicinity of
a vascular graft appear anatomically similar to an
abscess, thus making it sometimes difficult to distin-
guish between non-infected and infected prosthetic
grafts on CT images. Chacko et al. showed that FDG
PET was useful in 3 patients suspected of blood ves-
sel graft infection. In 2 patients, increased FDG uptake
corresponded with infection. Around the blood ves-
sel graft of the other patient, believed to be non-
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infected, no abnormal FDG uptake was seen.18 In a
recent study systematically comparing CT and FDG
uptake on PET in patients suspected of vascular graft
infection, the sensitivity of FDG PET (91%) was sig-
nificantly higher than that of CT (64%; P<0.05).
However, the specificity of FDG PET (64%) was low-
er than that of CT (86%; not significant). When the PET
criterion for infection was defined as focal abnormal
uptake, all the false-positive cases were categorized as
negative. With this alteration of the diagnostic criteria,
the specificity of FDG PET improved significantly
from 64% to 95% (P<0.05).47 In conclusion, FDG PET
seems to be a promising modality for the evaluation
of infected aortic grafts and may serve as a useful
tool for non-invasive diagnosis of this clinical problem
(Figures 1, 2). Moreover, FDG PET shows a diagnos-
tic performance superior to that of CT when specific
uptake patterns of FDG are included in the diagnos-
tic criteria. Because many of the false positive PET
results occurred in patients with recent graft implan-
tation, it is to be expected that specificity and positive
predictive value are even better after a certain period
after surgery. In addition, combined PET-CT-scans
are suspected to further increase the usefulness of
this imaging modality.
Other endovascular foci, such as septic throm-
bophlebitis or septic arteritis, can also be successful-
ly diagnosed by FDG PET, as has been shown in sev-
eral case reports and series.48, 77 In a retrospective
study, FDG PET correctly identified 9 patients with
septic thrombophlebitis due to central venous catheters,
while acute thrombosis did not lead to increased FDG
uptake in the remaining 27 patients with proven acute
or chronic thrombosis.78 FDG PET diagnosis of septic
thrombophlebitis resulted in therapeutic changes in
all patients. In a small case series, however, increased
FDG uptake was found in 4 patients at the distal end
of a central venous catheter.49 Catheter-related throm-
bosis was identified as the cause of FDG activity in 3
patients, whereas catheter-related infection was diag-
nosed in one patient. Further prospective studies are
necessary to decide whether FDG PET is useful in
diagnosing catheter-related infection.
Myocardial FDG uptake shows variable intra- and
inter-individual uptake patterns among other things
depending on blood glucose levels. FDG PET, there-
fore, is not likely to become the preferred diagnostic
technique to identify infectious endocarditis due to lim-
ited specificity. Focal myocardial FDG uptake, how-
ever, corresponded with echocardiographic localiza-
tion of infection in 6 patients with proven endo-
carditis.50 In our clinical experience, however, the
diagnostic usefulness of FDG PET in diagnosing endo-
carditis appears to be limited and the results of larg-
er prospective studies will be necessary to confirm
these early reports.
Figure 2.—A-D) This 61-year-old woman presented with a one day his-
tory of fever and chills. Since 5 years, she had an aortic arch prosthesis
(Bentall). Blood cultures repeatedly grew Staphylococcus aureus.
Thoracic computed tomography (CT) on day 2 was completely nor-
mal (not shown). Positron emission tomography-CT showed marked-
ly increased fluorodeoxyglucose uptake surrounding the aortic arch
prosthesis on day 5 after admission. During surgical replacement of
the aortic arch prosthesis and the aortic valve endocarditis and infec-
tion of the prosthesis was confirmed.
Figure 1.—A 85-year old female patient with MSRA-infected right hip
replacement. Image courtesy of Dr. Christofer Palestro, Long Island
Jewish Medical Center, New York.
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Metastatic infectious foci
Secondary metastatic infection is a well-known
complication of blood stream infections. Timely iden-
tification of metastatic complications, although critical,
is often difficult. In a retrospective study in 40 patients
with a high suspicion of metastatic complications after
blood stream infection, FDG PET diagnosed a clinically
relevant new focus in 45% of cases while on aver-
age, 4 conventional diagnostic tests had been per-
formed before FDG PET.51 It is concluded that FDG
PET appears to have a promising role in detecting
metastatic infectious foci in patients with a high lev-
el of clinical suspicion (Figure 3). A prospective study
further evaluating this subject is ongoing.
The immunocompromised host
In children with chronic granulomatous disease, a
primary immunodeficiency leading to granuloma for-
mation and numerous infections, FDG PET was com-
pared with CT in detecting active infective foci.52 PET
excluded 59 lesions suspicious for active infection on
CT and revealed 49 infective lesions not seen on CT.
All active infective lesions were identified by PET,
allowing targeted biopsy and identification of the
infective agent followed by specific antimicrobial treat-
ment or surgery.
Fever frequently complicates the management of
pediatric patients with terminal chronic liver failure
during the pretransplantation period. Non-hepatic ori-
gins of systemic infections may render a patient unsuit-
able for transplantation, whereas infections within
the liver may require organ resection for cure. In 11
children with biliary cirrhosis presenting with fever
during the waiting period for liver transplantation,
positive intrahepatic FDG uptake was shown to cor-
relate with infection (proven after liver transplantation)
in 5 children.53 In 6 children, no abnormal hepatic
FDG PET foci were found and no infections could
be detected in the liver. Standard imaging techniques
did not reveal abnormalities compatible with infection
in any of these children. In conclusion, in children pre-
senting with fever who are on waiting lists for liver
transplantation, information obtained by FDG PET
may be useful for decision-making on therapy and
suitability for liver transplantation. Jones et al. per-
formed FDG PET scans in 15 lung transplant recipients
suspected of infection or rejection.54 Rejection alone
did not increase FDG uptake possibly due to the
absence of neutrophil activation in acute rejection. It
is concluded that increased FDG uptake in these
patients is indicative of infection and not of rejection,
rendering FDG PET a useful diagnostic method that
could reduce the number of transbronchial biopsies
required during episodes of breathlessness after lung
transplantation.
In infectious diseases, abnormal FDG uptake is
caused by increased glucose uptake in activated leuko-
cytes. In case of severe neutropenia, it is questionable
whether FDG PET can be used for diagnosing infec-
tious diseases due to the markedly decreased number
of activated leukocytes at the site of infection. In 3
severely immunocompromised patients (chemother-
apy because of acute myeloid leukemia, bone marrow
transplant because of myelodysplastic syndrome and
high-dose salvage chemotherapy because of relapsed
high-grade non-Hodgkin’s lymphoma), however,
increased FDG uptake revealed foci of Candida and
Aspergillus abscesses, respectively.55 Mahfouz et al.
retrospectively studied 248 PET scans ordered in
patients with multiple myeloma either for staging dis-
ease progression or infection work-up.56 FDG PET
identified 165 infectious foci even in patients with
Figure 3.—A-D) Fluorodeoxyglucose (FDG) positron emission tomog-
raphy-computed tomography-scan in a 10-year-old child with
Streptococcus milleri bacteremia showing increased uptake of FDG in
the cervical spine and the lungs due to metastatic infectious lesions.
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severe neutropenia (in 30 cases). In 46 patients, infec-
tion was not identified by a regular diagnostic work-
up. In this study, FDG PET contributed to patient care
in 46% of all patients. It is concluded that FDG PET is
a useful tool for diagnosing and managing infections
in patients with multiple myeloma, even in the setting
of severe immunosuppression.
As early as 1995, FDG PET was described as a pos-
sible diagnostic technique for differentiation between
infectious central nervous system (CNS) foci and lym-
phoma in human immunodeficiency virus (HIV) infect-
ed patients.57 In a prospective case series of 18 patients
with HIV infection and focal CNS lesions, FDG PET
could accurately differentiate lymphoma from infec-
tions in 16 of 18 cases. Two cases of progressive mul-
tifocal leukoencephalopathy had high metabolic activ-
ity and could not be differentiated from lymphoma.58
In three other studies, FDG PET was also able to accu-
rately differentiate between a malignant (lymphoma)
and nonmalignant etiology in HIV infected patients
with CNS lesions.57, 59, 60 Biopsy, however, is often still
necessary to confirm the diagnosis of lymphoma or to
perform cultures to determine the exact etiology of
infectious foci, which limits the usefulness of FDG
PET in clinical practice. O’Doherty et al. studied the
use of FDG PET in 57 HIV-infected patients with FUO
and/or weight loss.59 FDG PET had a sensitivity of
92% and a specificity of 94% for localization of focal
pathology that needed treatment. High uptake of FDG
(greater than liver) had a positive predictive value of
95% for pathology needing treatment. In these patients,
FDG PET appears to be a potentially useful diagnos-
tic technique.
Various patterns of FDG accumulation in HIV-pos-
itive patients have been described previously and
hypothesized to potentially represent regions of active
HIV replication or nodal activation. Brust et al. eval-
uated FDG biodistribution visually and quantitative-
ly in HIV-negative individuals and various groups of
HIV-infected patients to determine the impact on the
pattern of nodal activation of HIV infection, the stage
of HIV infection and degree of viremia, and highly
active antiretroviral therapy (HAART).61 Abnormal
FDG accumulation occurred in the nodes of individ-
uals with detectable viral loads. Interruption of effec-
tive HAART resulted in the activation of previously qui-
escent nodal areas. Iyengar et al. investigated the abil-
ity of PET to detect and measure magnitude of lymph-
node involvement in 8 HIV-1-uninfected individuals
who had received licensed killed influenza vaccine, 12
patients recently infected with HIV-1, and 11 chron-
ic long-term HIV-1 patients who had stable viremia
(non-progressors).62 Node activation was more
localised after vaccination than after HIV-1 infection.
In early and chronic HIV-1 disease, node activation
was greater in cervical and axillary than in inguinal and
iliac chains. Non-progressors had small numbers of
persistently active nodes, most of which were surgi-
cally accessible, which may reflect microenviron-
mental niche selection. In a study by Scharko et al.,
FDG PET images from 15 patients with HIV-1 showed
distinct lymphoid tissue activation in the head and
neck during acute disease, a generalized pattern of
peripheral lymph-node activation at mid-stages, and
involvement of abdominal lymph nodes during late
disease.63 It is suggested that the anatomy of HIV-1
infection could encourage use of surgical or radio-
logical interventions to supplement chemotherapy in
the future.
Miscellaneous infectious diseases
FDG PET has been studied in patients with various
infectious and inflammatory diseases. In a small study
by Sugawara et al., FDG PET correctly identified the
infectious foci in 10 of 11 patients.64 In a retrospective
study, 55 FDG PET scans were performed in 48
patients with suspected focal infection or inflamma-
tion.65 A final diagnosis was established in 38 patients
(32 patients with an infectious disease). Of the total
number of scans, 65% were clinically helpful. The
positive predictive value of FDG PET in these 55
episodes of suspected infection or inflammation was
95% and the negative predictive value was 100%.
Ichiya et al. studied the usefulness of FDG PET in the
detection of various infectious foci in 24 patients with
lesions of bacterial, tuberculous and fungal origin.66
High FDG uptake was observed in 23 of 25 lesions
(92%). Two lesions, in which no abnormal uptake
was noted included one in the healing stage and the
other consisting of a thin-walled cavity. In a retro-
spective study by Jaruskova et al., either FDG PET or
FDG PET-CT was performed in 118 patients with pro-
longed fever.33 Infection was diagnosed in 21 patients,
systemic connective tissue disease in 17 patients, lym-
phoma in 3 patients, and inflammatory bowel dis-
ease in 2 patients. FDG PET or PET-CT contributed to
establishing a final diagnosis in 36% of all 118 patients.
Stumpe et al. studied FDG PET in 27 patients sus-
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pected of soft tissue infections.17 Sensitivity was 96%
on a per body region basis (dividing the body into 22
regions) and specificity was 99%. One false-negative
result was found in a patient with cholangitis. In a
small case series, increased FDG uptake is also found
in patients with brain abscesses.67 It is concluded that
FDG PET appears to be a highly sensitive method to
detect various infectious foci in many parts of the
body. Specificity is more difficult to estimate, but is
probably in the range from 70% to above 90%.
Fever of unknown origin
The value of FDG PET has been studied in several
studies in 292 patients with FUO65, 68-73 (Table II),
showing an overall helpfulness of FDG PET correct-
ed for study population of 36%, which is very high
compared to radiological techniques and [67Ga]citrate
scintigraphy. Comparing these studies, however, is
difficult. First of all, the definition of FUO was differ-
ent in each study. Second, the FDG PET technique in
the study by Meller et al.69 is inferior to the FDG PET
technique in the other studies. Furthermore, FDG PET
was performed at different stages of the diagnostic
process. The use of a structured diagnostic protocol
including FDG PET has reduced the chance of selec-
tion bias in the last FUO study.73 In this study, it was
also shown that FDG PET did not contribute in any of
the patients with normal C-reactive protein and ery-
throcyte sedimentation rate, so FDG PET is not indi-
cated in these patients.
When compared to conventional radiopharma-
ceuticals routinely used in clinical practice, such as
67Ga and 111In-labelled or 99mTc-labeled leukocytes,
advantages of FDG PET are higher resolution, sen-
sitivity in chronic low-grade infections, and high
accuracy in the central skeleton. Another major
advantage of FDG PET in the work-up of FUO is
the vascular FDG uptake in patients with vasculi-
tis.69, 79 A theoretical disadvantage is the impossibil-
ity to differentiate between malignancy and infectious
diseases or inflammation. In patients with FUO, how-
ever, this appears to be an advantage rather than a
drawback since all of these disorders are represent-
ed in this patient group and additional diagnostic
tests are needed in most cases. An obvious disad-
vantage is the relatively high cost and the lesser
availability of PET. However, as the number of PET
systems further increases, the high diagnostic yield
of FDG PET may very well become a cost-effective
modality, since adequate, early diagnosis limits the
number of other non-contributing (invasive) tests
required and the time to diagnosis and thus decreas-
TABLE II.—Studies evaluating the value of fluorodeoxyglucose positron emission tomography in patients with fever of unknown ori-
gin.
First author Study design FDG PET technique Conclusions
Meller et al.69 Prospective (n=20): comparison Dual-headed FDG PET helpful in 55%,
FDG PET and coincidence camera PPV 92%, NPV 75%,
[67Ga]citrate (n=18) FDG PET superior to [67Ga]citrate
Blockmans et al.68 Prospective (n=58): comparison Full ring PET scanner FDG PET helpful in 41%, 
to [67Ga]citrate (n=40) FDG PET superior to [67Ga]citrate
Lorenzen et al.70 Retrospective (n=16) Full ring PET scanner FDG PET helpful in 69%,
PPV 92%, NPV 100%
Bleeker-Rovers et al.65 Retrospective (n=35) Full ring PET scanner FDG PET helpful in 37%,
PPV 87%, NPV 95%
Kjaer et al.71 Prospective (n=19): comparison Full ring PET scanner FDG PET helpful in 16%, PPV 30%,
to [111In]granulocyte NPV 67%, [111In]granulocyte
scintigraphy helpful in 26%
Buysschaert et al.72 Prospective (n=74) Full ring PET scanner FDG PET helpful in 26%
Bleeker-Rovers et al.73 Prospective, multicenter (n=70) Full ring PET scanner FDG PET helpful in 33%,
PPV 70%, NPV 92%
FDG PET: fluorodeoxyglucose positron emission tomography; PPV: positive predictive value; NPV: negative predictive value.
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es the duration of hospitalization necessary for diag-
nostic purposes.
From two prospective studies comparing FDG
PET with [67Ga]citrate scintigraphy in a total of 58
patients with FUO, it was concluded that FDG PET
was superior to [67Ga]citrate scintigraphy, because
the diagnostic yield is at least similar to that of
[67Ga]citrate scintigraphy and the results are available
within hours instead of days.68, 69 Kjaer et al.71 con-
clude in their prospective study comparing FDG
PET with 111In-granulocyte scintigraphy in 19 patients
with FUO that 111In-granulocyte scintigraphy is supe-
rior to FDG PET, because of the high percentage of
false positive FDG PET scans (37%). Although
unnecessary tests should, of course, be prevented if
possible, it is very questionable whether a relative-
ly high percentage of false positive results is suffi-
cient justification to reject FDG PET as a valuable
diagnostic method in patients with FUO. In a recent-
ly published study, false positive FDG PET results
were responsible for less than 1% of all diagnostic
studies performed in patients with FUO despite the
fact that FDG PET was purposely over-interpreted to
provide high sensitivity. On the other hand, an
abnormal FDG PET scan leading to the underlying
cause of fever, deters the use of tests that are con-
sidered in most diagnostic protocols as second lev-
el screening investigations. Furthermore, FDG PET
has very high sensitivity for most malignant tumors
while 111In-granulocyte scintigraphy does not. In
addition, the therapeutic and prognostic conse-
quences of a delay in diagnosing a malignancy
responsible for FUO may occur in up to 25% of cas-
es. Therefore, we believe that high accuracy in diag-
nosing malignant disease should be an important
operational characteristic for recommended nuclear
medicine techniques in FUO patients. Based on the
results of prior studies that are a consequence of
the favorable characteristics of FDG PET, conven-
tional scintigraphic techniques may in the future be
replaced by FDG PET in the investigation of patients
with FUO in institutions where this technique is
available.
Differentiation between infection
and malignancy
In malignant diseases, generally higher SUV of
FDG are expected to be found when compared to
FDG accumulation in infectious or inflammatory dis-
orders. Bryant et al. studied the usefulness of SUV for
differentiation of infection and malignancy in soli-
tary pulmonary nodules in 585 patients.74 Although
higher SUV were related to a higher likelihood of
malignancy, many false positives and negatives were
found. For example, there was a 24% chance a sus-
picious nodule that had a maximal SUV of 0 to 2.5
was cancer. Sahlmann et al. investigated glucose
metabolism in chronic bacterial osteomyelitis by using
FDG PET and a dual time protocol.31 In patients with
chronic osteomyelitis, the median SUV did not change
significantly between 30 and 90 min, while the medi-
an SUV increased in patients with malignant bone
lesions. Although the authors speculate that this could
be useful for differentiation between infection and
malignancy, median and maximal SUV values and
changes in SUV over time showed considerable over-
lap in some patients with infection and patients with
malignant disease. In most patients, biopsy or micro-
biology results will still be needed to confirm the
diagnosis.
Conclusions and future directives
FDG PET has a lot to offer in visualization of var-
ious infectious foci in many organ systems. It is shown
to be useful in FUO and in patients suspected of
osteomyelitis, especially in cases of chronic low-
grade infections and in vertebral osteomyelitis. The
usefulness of FDG PET in suspected joint prosthesis
infection has been previously addressed. Although
sensitivity is very high, some authors reject the use of
FDG PET in favor of combined leukocyte scintigraphy
and bone scanning in patients with suspected pros-
thesis infections due to low specificity while others
advocate its use noting that specificity for the iden-
tification of infection markedly increases when FDG
accumulation is seen along the bone-prosthesis inter-
face.
FDG PET has shown promising results in vascular
graft infections and the evaluation of metastatic infec-
tious foci in patients with blood stream infections.
Since FDG uptake surrounding the graft or implant
can still be physiological in the early postoperative
period, further studies are needed to determine the
normal time course of FDG distribution between
surgery and FDG PET scanning so, in patients with
suspected infected vascular grafts or metallic implants
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scans can be interpreted with high specificity. The
usefulness of FDG PET in neutropenic patients
should also be further evaluated in larger clinical
studies before widespread use of this technique can
be advised.
Although FDG PET does not directly provide a
definitive diagnosis, i.e. a histological or a microbio-
logical diagnosis, it often provides anatomic localiza-
tion where a particular metabolic process is ongoing
and with the help of other techniques, such as biop-
sy and culture facilitates timely definitive diagnosis
and therapy. Since combined PET-CT scanners assist
the interpretation of the PET findings by exact local-
ization of lesions, the accuracy of FDG PET in diag-
nosing infectious diseases will most likely improve
further with the availability of hybrid PET-CT and
demonstrate its usefulness much in the same man-
ner as it has in oncology.
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